Fierce Pharma

NOVEMBER 6, 2023

The drug launched after an FDA approval in May 2023.

Sales 239

Sales FDA 239

Fierce Pharma

FEBRUARY 5, 2024

Less than two months after the FDA approved the combination treatment of Astellas and Pfizer’s Padcev and Merck’s Keytruda in first-line bladder cancer, the Japanese company has

Sales 286

Sales FDA 286

MedCity News

FEBRUARY 8, 2024

Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus’s cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates.

Sales 312

Sales Manufacturing FDA Biopharma 312

Fierce Pharma

MAY 2, 2024

Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat COPD could be delayed, as the FDA has requested additional efficacy data from two trials. The regulatory hurdle comes as Eylea showed stagnant sales, even though its new high-dose formula is seeing increased uptake.

Sales 195

Sales FDA 195

Fierce Pharma

OCTOBER 30, 2023

As an FDA decision draws closer on bluebird bio’s sickle cell disease gene therapy, the company has lined up a potential sale of a priority review voucher (PRV). | The company entered an advance agreement for a priority review voucher ahead of the FDA's decision on the sickle cell disease gene therapy prospect.

FDA 219

FDA Prospecting Sales 219

World of DTC Marketing

OCTOBER 21, 2021

The FDA’s “accelerated approval” program expedites the evaluation process for new treatments so that patients can have access to them sooner. Between 2011 and 2018, cumulative spending on 44 FDA-approved oral targeted therapy drugs was $3.5 appeared first on World of DTC Marketing.com.

FDA 234

FDA Insurance Prescription Medicine 234

Fierce Pharma

SEPTEMBER 27, 2023

Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. | The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. The partners plan to make Ryzumvi available in the U.S.

Pharmacology 232

Pharmacology FDA Sales 232

Fierce Pharma

JULY 27, 2023

Approved by the FDA in January 2022, Vabysmo already crossed the one-billion-dollar sales mark in the first half of 2023. .” | To Roche’s pharma chief Teresa Graham, no word better describes the company’s eye drug Vabysmo right now than “momentum.”

FDA 223

FDA Pharma Sales 223

Fierce Pharma

MAY 24, 2024

In a change of pace from the recent COVID-related business struggles for Pfizer, the drugmaker has picked up a valuable reward from the FDA in the form of a priority review voucher (PRV). |

FDA 253

FDA Sales Medical 253

World of DTC Marketing

JUNE 23, 2021

sales alone, which is above consensus estimates of around $7 billion to $8 billion, the team said. One agency FDA adviser, resigning from his committee post in protest, called it “probably the worst drug approval decision in recent U.S. I, therefore, find the FDA’s decision to be puzzling. Natalie Shure, The New Republic.

FDA 218

FDA Side effects Physicians Patients 218

MedCity News

AUGUST 29, 2023

It’s the third indication for the drug, which analysts project could top $4 billion in peak sales. Bristol Myers Squibb drug Reblozyl is now approved as a first-line therapy for anemia caused by myelodysplastic syndromes, a group of blood cancers.

FDA 284

FDA Sales Biopharma Pharma 284

MedCity News

JANUARY 18, 2024

BridgeBio will receive $500 million in exchange for royalties from sales of acoramidis, a drug currently under FDA review for treating heart complications caused by the rare disease transthyretin amyloidosis. The deal also refinances lending agreements, providing BridgeBio with access to additional capital.

FDA 300

FDA Sales Biopharma Pharma 300

Fierce Pharma

JULY 5, 2023

the same can’t be said for the cost of an FDA priority review voucher. Since 2017, the company has sold off three PRVs—getting less in return for each successive sale. While the price of just about everything has increased over the last six years in the U.S., Just ask Sarepta Therapeutics. | Just ask Sarepta Therapeutics.

FDA 210

FDA Sales 210

MedCity News

SEPTEMBER 5, 2023

Palforzia was the first FDA-approved drug for peanut allergy, but its sales were hampered by the Covid-19 pandemic. Peanut allergy therapy Palforzia, which Nestlé acquired in a multi-billion dollar deal, has been sold to allergy product company Stallergenes Greer.

Food 299

Food FDA Sales Biopharma 299

Fierce Pharma

JANUARY 31, 2024

More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Bi | Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path. The company is taking a $60 million charge, halting sales and terminating a confirmatory trial.

FDA 300

FDA Sales 300

Fierce Pharma

JUNE 20, 2023

Three weeks after the FDA warned that some pharmacies are making unauthorized versio | Novo Nordisk filed five lawsuits in four states on Tuesday, charging health spas, clinics and pharmacies with false advertising, trademark infringement and unlawful sales of compounded versions of diabetes and weight loss drugs Ozempic and Wegovy.

FDA 311

FDA Sales 311

Fierce Pharma

NOVEMBER 4, 2024

Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. |

Medical 183

Medical FDA Sales 183

Fierce Pharma

JULY 27, 2023

Securing FDA approvals last year for three drugs that each have peak sales potential of $4 billion bodes well for the long-term future of Bristol Myers Squibb. And it's projecting overall sales decline for 2023. Bristol Myers Squibb is entering a dark stage.

Sales 166

Sales FDA 166

Fierce Pharma

AUGUST 29, 2023

As Bristol lays off staffers and works through the painful loss of exclusivity for | The first-line anemia use in MDS represents a key milestone as Bristol Myers targets $4 billion in peak sales for the new medicine.

Sales 166

Sales Medicine FDA 166

Fierce Pharma

FEBRUARY 29, 2024

Despite a restricted FDA label, Sarepta Therapeutics has seen early commercial success with its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. | The company is quickly moving through Elevidys' eligible patient population while awaiting the FDA's decision on a broader label.

FDA 165

FDA Sales Patients 165

pharmaphorum

OCTOBER 21, 2024

billion in the first half of the year.

FDA 109

FDA Sales Pharma Patients 109

MedCity News

JUNE 27, 2022

Ipsen is paying $247 million to acquire Epizyme, a cancer drug developer with one FDA-approved product: follicular lymphoma therapy Tazverik. The drug is a modest seller now, but more cash could be paid out if the small molecule hits sales targets in coming years.

FDA 246

FDA Sales Biopharma Pharma 246

Fierce Pharma

NOVEMBER 2, 2023

But strong demand continues to push sales of the GLP-1/GIP agonist to new highs ahead of an FDA decision on weight loss. | As strong demand continues to push Mounjaro sales to new highs, Eli Lilly CEO David Ricks said the company is "not done with" manufacturing expansions.

Manufacturing 232

Manufacturing Sales FDA 232

Fierce Pharma

NOVEMBER 2, 2023

Ever since Novo Nordisk won FDA approval for its GLP-1 weight-loss med Wegovy more than 2 years ago, analysts and investors have been keeping a close eye on the blockbuster drug launch.

Manufacturing 215

Manufacturing FDA Sales 215

Fierce Pharma

AUGUST 1, 2024

sales of $304 million during the second quarter, Regeneron’s high-dose version of Eylea came up just short of analyst projections. | sales had declined in each of the previous three quarters. The launch of Regeneron's Eylea HD has helped the Eylea franchise to a rebound after U.S.

Manufacturing 204

Manufacturing Sales FDA 204

Fierce Pharma

FEBRUARY 28, 2024

After an initial FDA approval came later than anticipated, UCB is looking to quickly grow Bimzelx. The company is eying four new indications and potential peak sales of 4 billion euros. After a busy 2023 marked by multiple drug approvals, UCB isn’t resting on its laurels.

FDA 223

FDA Sales 223

Evolve Your Success

JANUARY 31, 2023

In this episode, Samuel Adeyinka interviews John Crowder who covers how to sell effectively in medical sales. Tune in now and get medical sales-ready! — Watch the episode here Listen to the podcast here Selling Effectively In Medical Sales With John Crowder We have with us another special guest. I’m wonderful.

Medical sales 162

Medical sales Sales Medical Training 162

Pharma Marketing Network

NOVEMBER 24, 2024

Always adhere to FDA guidelines and include clear disclaimers in campaigns. Example: Use analytics to identify which regions have higher sales for branded drugs and tailor campaigns accordingly. By adopting these strategies, you’re not just boosting sales—you’re transforming lives. But how do you stand out in a crowded market?

Pharmaceutical Sales 52

Pharmaceutical Sales Healthcare Healthcare Marketing 52

Infuse Medical

JUNE 23, 2020

As a sales or marketing professional in the medical device industry, you’ve probably heard the term “sales enablement”. But what exactly is medical sales enablement? Can it really help maximize your sales process and yield a higher ROI for your company? Medical Sales Enablement Defined. Let’s get started!

Medical sales 130

Medical sales Sales Medical Training 130

Evolve Your Success

OCTOBER 3, 2023

Diagnostic testing sales: where meticulous detail meets the human touch, changing the course of cancer care one relationship at a time. In this special episode for Breast Cancer Awareness Month, Veronica Vasek uncovers the challenges, triumphs, and the vital role that diagnostic sales reps play in the healthcare landscape.

Sales 162

Sales Medical sales Physicians Patients 162

Fierce Pharma

AUGUST 2, 2023

The convenience of shorter infusion time is a big selling point for TG Therapeutics’ newly FDA-approved multiple sclerosis drug Briumvi. | The convenience of shorter infusion time is a big selling point for TG Therapeutics’ newly FDA-approved multiple sclerosis drug Briumvi.

Sales 173

Sales FDA 173

pharmaphorum

JULY 10, 2024

After short but worrying delay, Arcutis gets FDA approval for flagship drug Zoryve in atopic dermatitis, which could further unlock sales growth

FDA 116

FDA Sales 116

Fierce Pharma

JUNE 20, 2024

AbbVie’s fast-growing Humira successor Skyrizi is already on a roll with skyrocketing sales. Since its original nod in 2019, AbbVie's IL-23 inhibitor has added several new uses over the years. Now, its fourth approved disease area is ulcerative colitis.

FDA 178

FDA Sales 178

pharmaphorum

MARCH 5, 2025

FDA starts a review of Roche's Gazyva as a treatment for lupus nephritis, an indication that analysts think could unlock renewed sales growth

FDA 99

FDA Sales 99

Infuse Medical

SEPTEMBER 17, 2020

It’s no secret that being a medical sales rep is a difficult, but rewarding, profession. Sales reps are usually at the forefront of this pressure and have to work hard to make sure the product’s value is understood while adhering to the FDA regulations. Pick Your Medical Device Sales Tech Wisely. Web Conferencing Tool.

Pharmaceutical Sales 130

Pharmaceutical Sales Sales Medical Pharmaceutical 130

pharmaphorum

OCTOBER 30, 2024

Novartis says FDA approval for frontline use of its leukaemia drug Scemblix will boost the number of eligible patients four-fold, as it hunts blockbuster sales

FDA 115

FDA Sales Patients 115

Fierce Pharma

NOVEMBER 2, 2023

Roche’s surge in sales for its long-acting macular degeneration drug Vabysmo showed that patients in the market are open to switching to another treatment. After gaining FDA approval for its high-dose Eylea, Regeneron racked up $43 million in sales in the U.S.

Sales 190

Sales FDA Marketing Patients 190